9 191 Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine Britt W.H. van der Arend1,2*, Nancy van Veelen1*, Joëlle E.T. de Ruijter1, Michael H. Olsen3,4, Antoinette MaassenVanDenBrink2, Gisela M. Terwindt1 Affiliations: 1 Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands 2Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands 3 Department of Internal Medicine 1, Holbaek Hospital, Denmark 4 Department of Regional Health Research, University of Southern Denmark, Denmark *Shared first author Frontiers in Neurology 2024;15:1387044
RkJQdWJsaXNoZXIy MjY0ODMw